222 related articles for article (PubMed ID: 15751736)
1. Protecting APOBEC3G: a potential new target for HIV drug discovery.
Stopak K; Greene WC
Curr Opin Investig Drugs; 2005 Feb; 6(2):141-7. PubMed ID: 15751736
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
Stopak K; de Noronha C; Yonemoto W; Greene WC
Mol Cell; 2003 Sep; 12(3):591-601. PubMed ID: 14527406
[TBL] [Abstract][Full Text] [Related]
3. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity.
Peng G; Lei KJ; Jin W; Greenwell-Wild T; Wahl SM
J Exp Med; 2006 Jan; 203(1):41-6. PubMed ID: 16418394
[TBL] [Abstract][Full Text] [Related]
4. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
[TBL] [Abstract][Full Text] [Related]
5. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
Sheehy AM; Gaddis NC; Malim MH
Nat Med; 2003 Nov; 9(11):1404-7. PubMed ID: 14528300
[TBL] [Abstract][Full Text] [Related]
6. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
Svarovskaia ES; Xu H; Mbisa JL; Barr R; Gorelick RJ; Ono A; Freed EO; Hu WS; Pathak VK
J Biol Chem; 2004 Aug; 279(34):35822-8. PubMed ID: 15210704
[TBL] [Abstract][Full Text] [Related]
7. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
Newman EN; Holmes RK; Craig HM; Klein KC; Lingappa JR; Malim MH; Sheehy AM
Curr Biol; 2005 Jan; 15(2):166-70. PubMed ID: 15668174
[TBL] [Abstract][Full Text] [Related]
8. [Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].
Fan B; Cen S; Jiang JD
Yao Xue Xue Bao; 2008 Jul; 43(7):678-82. PubMed ID: 18819469
[TBL] [Abstract][Full Text] [Related]
9. Identification of an HIV-1 replication inhibitor which rescues host restriction factor APOBEC3G in Vif-APOBEC3G complex.
Zhang S; Zhong L; Chen B; Pan T; Zhang X; Liang L; Li Q; Zhang Z; Chen H; Zhou J; Luo H; Zhang H; Bai C
Antiviral Res; 2015 Oct; 122():20-7. PubMed ID: 26241003
[TBL] [Abstract][Full Text] [Related]
10. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.
Mariani R; Chen D; Schröfelbauer B; Navarro F; König R; Bollman B; Münk C; Nymark-McMahon H; Landau NR
Cell; 2003 Jul; 114(1):21-31. PubMed ID: 12859895
[TBL] [Abstract][Full Text] [Related]
11. APOBEC3G targets human T-cell leukemia virus type 1.
Sasada A; Takaori-Kondo A; Shirakawa K; Kobayashi M; Abudu A; Hishizawa M; Imada K; Tanaka Y; Uchiyama T
Retrovirology; 2005 May; 2():32. PubMed ID: 15943885
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.
Marin M; Rose KM; Kozak SL; Kabat D
Nat Med; 2003 Nov; 9(11):1398-403. PubMed ID: 14528301
[TBL] [Abstract][Full Text] [Related]
13. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
[TBL] [Abstract][Full Text] [Related]
14. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).
Schröfelbauer B; Chen D; Landau NR
Proc Natl Acad Sci U S A; 2004 Mar; 101(11):3927-32. PubMed ID: 14978281
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.
Santa-Marta M; da Silva FA; Fonseca AM; Goncalves J
J Biol Chem; 2005 Mar; 280(10):8765-75. PubMed ID: 15611076
[TBL] [Abstract][Full Text] [Related]
16. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.
Franca R; Spadari S; Maga G
Med Sci Monit; 2006 May; 12(5):RA92-8. PubMed ID: 16641889
[TBL] [Abstract][Full Text] [Related]
17. [Research methods of anti-HIV-1 inhibitors targeting at Vif-APOBEC3G axis].
Qiao X; Zhang W; Li Z; Zeng Y
Zhongguo Zhong Yao Za Zhi; 2011 Mar; 36(6):806-9. PubMed ID: 21710755
[TBL] [Abstract][Full Text] [Related]
18. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.
Conticello SG; Harris RS; Neuberger MS
Curr Biol; 2003 Nov; 13(22):2009-13. PubMed ID: 14614829
[TBL] [Abstract][Full Text] [Related]
19. Cellular interactions of virion infectivity factor (Vif) as potential therapeutic targets: APOBEC3G and more?
Carr JM; Davis AJ; Feng F; Burrell CJ; Li P
Curr Drug Targets; 2006 Dec; 7(12):1583-93. PubMed ID: 17168833
[TBL] [Abstract][Full Text] [Related]
20. New insights into the role of Vif in HIV-1 replication.
Schröfelbauer B; Yu Q; Landau NR
AIDS Rev; 2004; 6(1):34-9. PubMed ID: 15168739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]